High Throughput Bioprinting of Tumour Models for Drug Development and Oncology Research

Información del proyecto

TUMOURPRINT

Identificador del acuerdo de subvención: 829846

DOI

10.3030/829846

Proyecto cerrado

Fecha de la firma de la CE 29 Octubre 2018

Fecha de inicio 1 Septiembre 2018

Fecha de finalización 31 Enero 2021

Financiado con arreglo a

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Coste total

€ 3 500 467,50

Aportación de la UE

€ 2 450 327,25

Coordinado por

BICO GROUP AB
Sweden

Periodic Reporting for period 3 - TUMOURPRINT (High Throughput Bioprinting of Tumour Models for Drug Development and Oncology Research)

Período documentado: 2020-09-01 hasta 2021-01-31

Resumen del contexto y de los objetivos generales del proyecto

CELLINK will develop and commercialise TumourPrint - a high throughput platform for bioprinting of live tumour models for pharmaceutical drug development and large-scale cancer research. Bioprinting constitutes the most advanced method for fabricating fidel tissue models, using live cells in combination with cell-instructive bioinks (specially formulated hydrogels that provide cells with an optimal environment for survival, growth and proper 3D development). The high throughput platform - completely new to the market - is designed according to user needs. It will revolutionise drug development processes through serial production of fidel cancer models in an automated, precise and reproducible way. The platform offers unparalleled printing capacity and is integrated with robotics and none-destructive analytical methods capable of scoring drug responses in printed constructs.

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

In the first reporting period significant progress has been achieved regarding the hardware and software components of the platform. The progress achieved allows the team to intensify development and validation activities envisaged for the second reporting period.
In PR2 the project is proceeding according to the time plan and in line with our expectations. The major deliverables and milestones have been submitted to the EU. In the PR2 we have achieved Milestone 2, Milestone 3 and Milestone 5.

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

Current oncology approaches principally rely on unsatisfactory 2D mono-cell cultures and animal models to predict outcomes in humans, resulting in exasperatingly high attrition rates of cancer drug candidates in clinical trials. The economic and ethically challenging implications of failed trials provide CELLINK with a unique value proposition to drive willingness-topay for their disruptive platform. TumourPrint will address today’s pharmaceutical challenges by producing tumour models capable of mimicking size, heterogeneity and vascularity of the human tumour microenvironment in a fidel way. CELLINK has a proven track-record of successfully developing and commercialising products according to user needs; they developed the world’s first universal bioink, have commercialized three generations of bioprinters and optimised 18 cellspecific bioinks. Since the company’s establishment in 2016, CELLINK has commercialised its technology in over 40 countries, grown its organisation ten-fold and secured collaborations with several global pharmaceutical giants.

Company logo